Fibroscan liver stiffness (LMS) and controlled attenuation parameter (CAP) in the evaluation of cardiovascular risk assessment in patients with NAFLD. Issue 1 (February 2018) - Lombardi, R.; Petta, S.; Giannetti, A.; Boemi, R.; Pisano, G.; Bertelli, C.; Craxi, A.; Fargion, S.; Fracanzani, A.L.